PharmaSGP successfully secures funding framework up to EUR 160 million (German)

rheumatic pain and Restaxil® for neuralgic pain ^

DGAP-News: PharmaSGP Holding SE / Keywords: Financing

PharmaSGP successfully secures the funding framework up to EUR 160 million

Euro

The best jobs of the day

Find the best job offers now and
be notified by e-mail.

07/21/2022 / 07:29

The issuer / publisher is responsible for the content of the application.

————————————————– —————————————

PharmaSGP successfully secures the funding framework up to EUR 160 million

Euro

Gräfelfing, July 21, 2022 – After strong organic growth and

successful acquisition and integration of four OTC brands

Baldriparan®, Formigran®, Spalt® and Kamol® from the GlaxoSmithKline group

(GSK) in the second half of 2021, PharmaSGP Holding SE reached

record sales of EUR 65.3 million in the last financial year.

Investors could participate in this success in the form of a dividend of the amount

50.5% of the group’s profit for the period. Also in the first quarter

In 2022, PharmaSGP continued the dynamic corporate development of the company

compared to previous quarters and generated a sales increase of 67%

last year. The German pharmaceutical company is fully committed to 2022.

turnover from 78 to 82 million euros, corrected

EBITDA margin of 30% to 33% based on sales.

The next milestone is now scheduled for mid-2022.

Syndicated financing with four banking partners for a period of five

years successfully completed. Thanks to the new syndicated loan

one existing debt capital of € 85 million, which for

The funds used for the acquisition of GSK were canceled and converted into one

transferred long-term structure. PharmaSGP, on the other hand, is available effective immediately

additional funding potential of up to 75

Millions of euros available to an exceptional European

Strengthen the distribution platform with further acquisitions.

Chief Financial Officer Michael Rudolf: “Smooth integration of GSK’s portfolio and

to demonstrate our very dynamic business development over the last few quarters

impressive that we can create significant added value for

our investors can create. This is possible because PharmaSGP is over

a scalable, pan-European platform for the development of new brands

they integrate very effectively thanks to established processes and structures

to let. In addition to strong organic growth, we continue to build

Increase in sales and profits thanks to selective M&A activities. New

The financing structure gives us long-term financing and

Planning security as well as the necessary flexibility for our follow-up

investments.”

CONTACT

Cometis AG

Claudius Krause

Phone: + 49-611-20585528

E-mail: [email protected]

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with

diversified portfolio of over-the-counter drugs

(over-the-counter “OTC”) and other health products that they focus on

be sold through the pharmacy sales channel. Drugs z

the company relies mainly on natural pharmaceuticals

Active ingredients with documented effectiveness and little known

side effects.

The company’s main brands cover chronic indications, including:

rheumatic and neuralgia and other age-related pains

Suffer. In Germany, PharmaSGP is involved in the RubaXX® brand families

rheumatic pain and Restaxil® for neuralgic pain (also:

neuralgia) a leader in the market of systemic, chemical-free painkillers.

In addition, PharmaSGP offers leading products for sexual weakness

and dizziness. Since the launch of the first product, z

current product portfolio in 2012 PharmaSGP has its own business model

successfully in other European countries, incl. in Austria, Italy,

Establishment of Belgium, Spain and France. It was in September 2021.

The product portfolio around the Baldriparan®, Formigran®, Spalt® and Kamol® brands

expanded, and with it an indication of areas of pain and sleep disorders

further developed or developed. The sales area was around Switzerland

and spread to Eastern Europe.

PharmaSGP generated sales of EUR 65.3 million in 2021

with adjusted EBITDA margin of 29.7%.

In order to further strengthen its competitive position, PharmaSGP plans to increase the number

Increasing the indications covered by their product offer

as well as expanding its presence in Europe and its development strategy

in particular by taking advantage of selected M&A opportunities

speed up.

————————————————– —————————————

07.21.2022 publication of corporate news / financial announcement,

provided by DGAP – EQS Group AG service.

The issuer / publisher is responsible for the content of the application.

DGAP’s distribution services include statutory reporting requirements,

Corporate / financial news and press releases.

Media archive at http://www.dgap.de

————————————————– —————————————

German

Company: PharmaSGP Holding SE

Lochhamer’s punch 21

82166 Graefelfing

Germany

E-mail: [email protected]

Web: https://pharmasgp.com

ISIN: DE000A2P4LJ5

WKN: A2P4LJ

Exchanges: Regulated market in Frankfurt (Prime Standard);

Open market in Berlin, Dusseldorf, Munich

EQS message ID: 1402475

End of news DGAP news service

————————————————– —————————————

1402475 07/21/2022

°

Leave a Comment